EP1613732A4 - Complexes intracellulaires utilises comme biomarqueurs - Google Patents

Complexes intracellulaires utilises comme biomarqueurs

Info

Publication number
EP1613732A4
EP1613732A4 EP20040758577 EP04758577A EP1613732A4 EP 1613732 A4 EP1613732 A4 EP 1613732A4 EP 20040758577 EP20040758577 EP 20040758577 EP 04758577 A EP04758577 A EP 04758577A EP 1613732 A4 EP1613732 A4 EP 1613732A4
Authority
EP
European Patent Office
Prior art keywords
biomarkers
intracellular complexes
intracellular
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20040758577
Other languages
German (de)
English (en)
Other versions
EP1613732A2 (fr
Inventor
Sharat Singh
M Youssouf Badal
Xuenguang Jin
Hossein Salimi-Moosavi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Monogram Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/623,057 external-priority patent/US7105308B2/en
Application filed by Monogram Biosciences Inc filed Critical Monogram Biosciences Inc
Publication of EP1613732A2 publication Critical patent/EP1613732A2/fr
Publication of EP1613732A4 publication Critical patent/EP1613732A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP20040758577 2003-04-01 2004-03-30 Complexes intracellulaires utilises comme biomarqueurs Withdrawn EP1613732A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US45988803P 2003-04-01 2003-04-01
US10/623,057 US7105308B2 (en) 2002-07-25 2003-07-17 Detecting receptor oligomerization
US49448203P 2003-08-11 2003-08-11
US50803403P 2003-10-01 2003-10-01
US51294103P 2003-10-20 2003-10-20
US52325803P 2003-11-18 2003-11-18
PCT/US2004/009805 WO2004087887A2 (fr) 2003-04-01 2004-03-30 Complexes intracellulaires utilises comme biomarqueurs

Publications (2)

Publication Number Publication Date
EP1613732A2 EP1613732A2 (fr) 2006-01-11
EP1613732A4 true EP1613732A4 (fr) 2012-03-14

Family

ID=33136354

Family Applications (3)

Application Number Title Priority Date Filing Date
EP04759065A Withdrawn EP1613961A4 (fr) 2003-04-01 2004-03-30 Complexes de recepteurs de surface utilises comme biomarqueurs
EP04759064.1A Expired - Lifetime EP1613205B1 (fr) 2003-04-01 2004-03-30 Complexes de recepteurs de surface erbb utilises comme biomarqueurs
EP20040758577 Withdrawn EP1613732A4 (fr) 2003-04-01 2004-03-30 Complexes intracellulaires utilises comme biomarqueurs

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP04759065A Withdrawn EP1613961A4 (fr) 2003-04-01 2004-03-30 Complexes de recepteurs de surface utilises comme biomarqueurs
EP04759064.1A Expired - Lifetime EP1613205B1 (fr) 2003-04-01 2004-03-30 Complexes de recepteurs de surface erbb utilises comme biomarqueurs

Country Status (6)

Country Link
EP (3) EP1613961A4 (fr)
JP (2) JP2006521821A (fr)
AU (3) AU2004230700A1 (fr)
BR (3) BRPI0408961A (fr)
CA (3) CA2521077A1 (fr)
WO (3) WO2004091384A2 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
AU2004230700A1 (en) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Surface receptor complexes as biomarkers
BRPI0413471A (pt) * 2003-08-11 2006-10-17 Monogram Biosciences Inc métodos para detectar um ou mais complexos de proteìnas e para detectar um complexo em uma amostra biológica
US7402399B2 (en) * 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
BRPI0515581A (pt) * 2004-09-22 2008-07-29 Tripath Imaging Inc métodos e produtos de programa de computador para análise e otimização de candidatos marcadores para prognóstico de cáncer
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
CA2647843A1 (fr) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection de proteines dans des cellules neoplasiques en circulation
CA2663595A1 (fr) * 2006-08-07 2008-02-14 The Board Of Regents Of The University Of Texas System Schemas proteomiques de pronostic du cancer et signatures predictives
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
AU2007324868B2 (en) 2006-11-28 2014-03-20 Daiichi Sankyo Europe Gmbh Activated HER3 as a marker for predicting therapeutic efficacy
PT2716301T (pt) 2007-02-16 2017-07-04 Merrimack Pharmaceuticals Inc Anticorpos contra erbb3 e suas utilizações
CN101802618B (zh) * 2007-07-13 2015-02-25 雀巢产品技术援助有限公司 利用基于抗体的阵列选择肺癌治疗药物
EP2235536A4 (fr) 2007-12-20 2011-05-04 Lab Corp America Holdings Procédés de diagnostic du her-2
NZ617520A (en) 2008-02-25 2015-05-29 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
US8168755B2 (en) * 2008-05-07 2012-05-01 Eutropics Pharmaceuticals, Inc. Antibodies specific to heterodimers of Bcl-2 family and uses thereof
UA104868C2 (uk) * 2008-08-15 2014-03-25 Меррімак Фармасьютікалз, Інк. Спосіб лікування пацієнта, що має неопластичну пухлину, відповідно до спрогнозованої реакції
CA2764386C (fr) 2008-12-01 2018-05-01 Laboratory Corporation Of America Holdings Anticorps p35-her2 et leurs utilisations
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
CN102439452B (zh) * 2009-01-15 2015-04-15 美国控股实验室公司 通过测量her-2表达确定患者应答的方法
AU2010229924B2 (en) 2009-03-24 2016-07-21 Biocept, Inc. Devices and methods of cell capture and analysis
US20120100538A1 (en) 2009-03-24 2012-04-26 Biocept, Inc. Devices and methods of cell capture and analysis
NZ596468A (en) 2009-05-14 2013-11-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
AU2010273319B2 (en) 2009-07-15 2015-01-22 Nestec S.A. Drug selection for gastric cancer therapy using antibody-based arrays
PT3351558T (pt) 2009-11-13 2020-04-09 Daiichi Sankyo Europe Gmbh Material e métodos para tratamento ou prevenção de doenças associadas a her-3
US8895001B2 (en) 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
US20140248291A1 (en) * 2011-03-30 2014-09-04 The Uab Research Foundation Modulation of Cellular Migration
KR101851425B1 (ko) * 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
EP2863920B1 (fr) 2012-06-20 2023-03-22 Eutropics Pharmaceuticals, Inc. Dérivés de quinoline pour l'utilisation dans le traitement du cancer du sein
US20160038503A1 (en) 2012-11-21 2016-02-11 David Richard Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
US20160041171A1 (en) * 2013-04-05 2016-02-11 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
SG11201509367RA (en) * 2013-05-21 2015-12-30 Nestec Sa Methods for predicting and improving the survival of colorectal cancer patients
WO2015017788A1 (fr) 2013-08-01 2015-02-05 Eutropics Pharmaceuticals, Inc. Méthode permettant de prédire la sensibilité d'un cancer
JP6538044B2 (ja) 2013-10-30 2019-07-03 ユートロピクス ファーマシューティカルズ， インコーポレイテッド 化学療法感受性および化学毒性を判定する方法
WO2015100459A2 (fr) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
WO2016115105A1 (fr) 2015-01-12 2016-07-21 Eutropics Pharmaceuticals, Inc. Essai de diagnostic dépendant du contexte pour guider le traitement du cancer
WO2016127220A1 (fr) * 2015-02-13 2016-08-18 The University Of Queensland Procédés de classement des tumeurs et leurs utilisations
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
CN108780089B (zh) 2016-03-15 2020-09-08 美国控股实验室公司 评估细胞间的蛋白质相互作用的方法
US20200355694A1 (en) * 2017-11-20 2020-11-12 Konica Minolta, Inc. Drug Evaluation Method
IT201800008274A1 (it) * 2018-08-31 2020-03-02 Alifax Srl Metodo immunometrico per analisi cliniche biologiche

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024205A1 (fr) * 1994-03-07 1995-09-14 New York University Medical Center Procede et compositions de traitement du cancer du sein
WO2003068808A1 (fr) * 2002-02-13 2003-08-21 Garvan Institute Of Medical Research Nouveaux complexes proteiques et utilisations associees
WO2003076649A1 (fr) * 2002-03-05 2003-09-18 Aclara Biosciences, Inc. Analyse multiplex au moyen de sensibilisateurs fixes a une membrane
WO2004091384A2 (fr) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Complexes de recepteurs de surface erbb utilises comme biomarqueurs
WO2005037071A2 (fr) * 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Analyse de la voie de signalisation de la tyrosine kinase de recepteur pour diagnostic et therapie

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5597531A (en) 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
JP3464798B2 (ja) 1992-07-31 2003-11-10 デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 光活性化化学発光基質
US5811098A (en) 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US5693271A (en) 1994-09-01 1997-12-02 Chase Industries, Inc. Rotationally molding an insulated plastic molded door with integral hinge
US5599631A (en) 1995-03-08 1997-02-04 Eastman Kodak Company Fluorinated elastomer/fluorinated resin compositions for toner fusing members
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6095661A (en) 1998-03-19 2000-08-01 Ppt Vision, Inc. Method and apparatus for an L.E.D. flashlight
ES2252972T3 (es) * 1998-09-08 2006-05-16 Agouron Pharmaceuticals, Inc. Modificaciones de la proteina vegfr-2 y procedimiento de uso.
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6514700B1 (en) * 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US6627400B1 (en) * 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
US6673550B2 (en) 1999-04-30 2004-01-06 Aclara Biosciences, Inc. Electrophoretic tag reagents comprising fluorescent compounds
US6346384B1 (en) 2000-03-27 2002-02-12 Dade Behring Inc. Real-time monitoring of PCR using LOCI
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
JP4796259B2 (ja) 2000-05-04 2011-10-19 シーメンス・ヘルスケア・ダイアグノスティックス・プロダクツ・ゲーエムベーハー 複数のアナライトの検出において使用するための組成物
US6547654B2 (en) 2000-07-22 2003-04-15 Americo Del Raso Automatic abrasive sleeve tightening means and quick release system for an oscillating spindle sander
WO2002068668A2 (fr) * 2001-02-22 2002-09-06 Immunex Corporation Compositions et procedes de production de culture cellulaire
EP1506399A2 (fr) 2001-05-21 2005-02-16 Aclara BioSciences, Inc. Procedes et compositions pour l'analyse de proteines
WO2003006947A2 (fr) 2001-07-09 2003-01-23 Aclara Biosciences, Inc. Methode et composition de criblage cellulaire
CA2354690A1 (fr) 2001-07-20 2001-10-27 Jan Prinzmetal Tapis
US6545102B1 (en) * 2001-09-27 2003-04-08 Lumigen, Inc. Polymer-supported photosensitizers
US7910314B2 (en) * 2002-03-01 2011-03-22 Roger Williams Hospital Shc protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
PT2263691E (pt) * 2002-07-15 2012-11-12 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)
KR20050025669A (ko) * 2002-07-25 2005-03-14 아클라라 바이오사이언시스 인코퍼레이티드 수용체 올리고머화의 검출

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024205A1 (fr) * 1994-03-07 1995-09-14 New York University Medical Center Procede et compositions de traitement du cancer du sein
WO2003068808A1 (fr) * 2002-02-13 2003-08-21 Garvan Institute Of Medical Research Nouveaux complexes proteiques et utilisations associees
WO2003076649A1 (fr) * 2002-03-05 2003-09-18 Aclara Biosciences, Inc. Analyse multiplex au moyen de sensibilisateurs fixes a une membrane
WO2004091384A2 (fr) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Complexes de recepteurs de surface erbb utilises comme biomarqueurs
WO2005037071A2 (fr) * 2003-10-14 2005-04-28 Monogram Biosciences, Inc. Analyse de la voie de signalisation de la tyrosine kinase de recepteur pour diagnostic et therapie

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
See also references of WO2004087887A2 *
SHINODA SACHIKO ET AL: "Interaction of 14-3-3 with Bid during seizure-induced neuronal death.", JOURNAL OF NEUROCHEMISTRY, vol. 86, no. 2, July 2003 (2003-07-01), pages 460 - 469, XP002667074, ISSN: 0022-3042 *
ZHA J ET AL: "Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL", CELL, CELL PRESS, US, vol. 87, 15 November 1996 (1996-11-15), pages 619 - 628, XP002110634, ISSN: 0092-8674, DOI: 10.1016/S0092-8674(00)81382-3 *

Also Published As

Publication number Publication date
AU2004230700A1 (en) 2004-10-28
CA2521106A1 (fr) 2004-10-14
EP1613732A2 (fr) 2006-01-11
AU2004225439A1 (en) 2004-10-14
WO2004087887A2 (fr) 2004-10-14
CA2521077A1 (fr) 2004-10-28
WO2004087887A3 (fr) 2006-06-15
EP1613205B1 (fr) 2013-04-24
EP1613205A4 (fr) 2006-11-29
EP1613961A2 (fr) 2006-01-11
EP1613205A2 (fr) 2006-01-11
WO2004092353A3 (fr) 2005-03-03
BRPI0408950A (pt) 2006-03-28
WO2004091384A3 (fr) 2005-12-29
EP1613961A4 (fr) 2007-03-07
CA2521082A1 (fr) 2004-10-28
WO2004092353A2 (fr) 2004-10-28
JP2006521821A (ja) 2006-09-28
WO2004091384A2 (fr) 2004-10-28
BRPI0408961A (pt) 2006-10-31
BRPI0408928A (pt) 2006-09-12
JP2006523314A (ja) 2006-10-12
AU2004229348A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
EP1613732A4 (fr) Complexes intracellulaires utilises comme biomarqueurs
IL174020A0 (en) Antigen-scaffold complexes
DE602004023400D1 (en) Lies
GB0322140D0 (en) Combinations
ZA200602792B (en) Multigame selection
GB0304515D0 (en) Standard
HK1081463A1 (en) Antineplastic combinations
TW568408U (en) Slide structure
DE502004009243D1 (en) Spirocyclische cyclohexan-derivate
AU155161S (en) Case
ZA200703827B (en) New pyridothlenopyrimidine derivates
DE502004003476D1 (en) Standfuss
DE502004006683D1 (en) Injection-locked-oscillator-schaltkreis
DE502004004146D1 (en) Pyrazolverbindungen
DE112004002769D2 (en) Schienengeführtes transportsystem
GB0311208D0 (en) Feature based caricaturing
DE502004011343D1 (en) Rotorspinnmaschine
DE10394343D2 (en) Berührungslose biometrische erkennung
AU155596S (en) Case
IL174218A0 (en) Ligands
EP1702851A4 (fr) Tiroir a encoche
GB0313709D0 (en) Ligands
GB0327016D0 (en) Russell block
TW573910U (en) Pivot
GB0327706D0 (en) Ligand

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051026

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20060817BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120210

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/53 20060101AFI20120203BHEP

Ipc: G01N 33/574 20060101ALI20120203BHEP

Ipc: G01N 33/542 20060101ALI20120203BHEP

17Q First examination report despatched

Effective date: 20150326

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171003